Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

South Africa Plans Antiretrovirals

by Michael McCoy
February 20, 2012 | A version of this story appeared in Volume 90, Issue 8

The South African government is in discussions with Lonza and the local firm Pelchem about building a $200 million joint-venture facility that would make active pharmaceutical ingredients (APIs) for antiretroviral drugs. One goal of the venture, called Ketlaphela, is to reduce the country’s dependence on imported APIs for drugs that treat HIV and AIDS. Another is to develop downstream applications for South Africa’s fluorite reserves. Several important antiretrovirals contain fluorine. At present, state-owned Pelchem is the only South African company to make fluorochemicals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.